Strengths and limitations The main strength of this study is that, as follow up to the maiden use of DFG as an implant for orbital volume replacement post- enucleation in Ghanaian children in same population, there is still a high success rate of graft growth. However, www.selleckchem.com/products/SRT1720.html the use of serial photographs for demonstrating graft growth rather than neuroimaging studies (such as MRI or CT Scan), the limited number of patients studied as well as the short follow up period were the possible limitations of this

study. Recommendation There is the need for a larger series with long term follow up and a randomized controlled study to compare the use of DFG with synthetic implants for better outcome for volume replacement in Ghanaian children with anophthalmia. Conclusion Ninety-three percent of the dermis fat graft implanted post-enucleation in our paediatric patients showed success in volume increase, LBH589 in vivo good prosthetic fitting and good facial symmetry. Minor complications

were encountered except a macrocyst and graft necrosis. Acknowledgement We acknowledge the contributions of Mr. Benjamin Abaidoo the senior research assistant and nurses of the paediatric eye centre of the Ophthalmology Unit, Korle-Bu Teaching Hospital, Ghana. We also acknowledge Dr George Obeng Adjei of the University of Ghana Medical School, for reading through the manuscript.
Infection with Human Immunodeficiency Virus (HIV) and its progression to Acquired Immunodeficiency Syndrome (AIDS) have been a global crisis and a big challenge plaguing the healthy living of human today. It erodes Resminostat both social and economic development as a result of its great influence on family stability, life expectancy and economic development.1 The burden is high globally as it remains the greatest

health crisis facing the world today. There are approximately 34 million people currently living with HIV and nearly 30 million people have died of AIDS-related causes since the beginning of the epidemic.2,3 The highest proportion of people living with HIV (97%) resides in low- and middle-income countries, particularly in sub- Saharan Africa.4 The use of highly active antiretroviral therapy (HAART) has resulted in a significant reduction in the morbidity and mortality related to AIDS. HAART is defined as the concurrent use of a combination of three or more ARV drugs to suppress HIV replication. It represents the current standard of care of antiretroviral therapy (ART) for HIV-infected patients.5 This strategy evolved from the recognition that treatment of chronic HIV infection with only one or two ARV drugs may result in rapid treatment failure and the development of resistance to the ARV drugs, which may compromise future therapeutic options.5,6 About a quarter of patients on ART discontinued the treatment within the first eight months due to treatment failure, adverse drug toxicity or non-compliance with the therapy.